ArticleBioinformatics and biology insights2025
Bayesian Inference for Drug Discovery by High Negative Samples and Oversampling.
Article in Bioinformatics and biology insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug repositioning holds great promise for reducing the time and cost associated with traditional drug discovery, but it faces significant challenges related to data imbalance and noise in negative samples. In this article, we introduce a novel method leveraging high negative oversampling (HNO) to address these challenges. Our approach integrates HNO with advanced techniques such as network-based graph mining, matrix factorization, and Bayesian inference, specifically designed for imbalanced data scenarios. Constructing high-quality negative samples is crucial to mitigate the detrimental effects of noisy negative data and enhance model performance. Experimental results demonstrate the efficacy of our approach in enhancing the performance of drug discovery models by effectively managing data imbalance and refining the selection of negative samples. This methodology provides a robust framework for improving drug repositioning, with potential applications in broader biomedical domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.